Business Development & Licensing

A partnership with Servier means working closely with dedicated experts capable of implementing and developing alliances in over 90 countries.

A long-term and personalized relationship

The scope and complexity of science today require an open and cooperative network between all stakeholders in research. This is why we are always actively searching for research partnerships, with academic organizations as well as other pharmaceutical groups and biotechnology companies. Choosing a partnership with us means long-term investment, via our foundation-based structure. It means choosing scientific and medical excellence with our top scientists and extensive clinical expert network. Each partnership is unique, and creates a personalized relationship.

What we can offer you

A long-term and personalized relationship.
Proven track record in clinical development, including large-scale outcome studies
Strong network of contacts and an excellent reputation with top experts in the pharmaceutical sector.
Considerable R&D capabilities, including 1 900 exclusively dedicated staff in France and 16 International Centres for Therapeutic Research.
High level of commitment and scientific expertise.
Partnerships managed by dedicated teams of alliance professionals certified by ASAP.
Presence or commercial activity in more than 90 countries.

What we are looking for in business development

We are seeking opportunities in our 5 areas of research and development:

We are interested in all innovative “best-in-class” products, from the target stage to late-stage clinical trials, provided they bring true therapeutic innovation to areas of unmet needs.
We are also interested in licensing marketed, or near-market, products that complement our existing portfolio.
Out-licensing: We are looking for partners in the United States and Japan to license some of our drug candidates and medicinal products, and global partners for non-strategic products.
What types of agreements? - Global rights with or without the United States and Japan - Local and regional agreements - R&D collaborations starting immediatly or after option exercise
  • Heart failure
  • Atrial fibrillation
  • Arrhythmia
  • Stroke
  • Hypertension
  • Coronary Artery Disease
  • Dyslipidemia
  • Venous disease

Cancer signaling pathways:

  • Apoptosis: focus on the resistance of cancer cells to programmed death
  • Highly validated targets with challenging druggability

Immune-oncology:

  • Allogenic CAR T cells
  • T cell engagers
  • New Immune-oncology targets (check point inhibitors)

Mid to late stage assets:

  • Showing convincing signs of clinical activities
  • Preference for gastro-intestinal tumors or hematological malignancies
  • Type 2 Diabetes
  • NASH
  • Diabetic Kidney Disease (DKD)

Only if Proof of Concept (POC) positive:

  • Diabetic Retinopathy
  • Non-injectable insulin

Any late-stage registered product or innovative therapeutic solution that may be of interest for diabetic patients

In research phase:

Neurodegenerative diseases associated with aging, e.g.

  • Alzheimer’s disease
  • Parkinson’s disease

Proteinopathies focus:

  • Protein pathogenicity
  • Protein clearance
  • Neuroinflammation
  • Neuroprotection

In preclinical and development phases:

  • Parkinson’s disease
  • Autism Spectrum Disorders
  • Acute stroke and post-stroke recovery
  • Multiple Sclerosis

Related rare disorders: Amyotrophic Lateral Sclerosis, Huntington’s disease, Traumatic Brain Injury, Rett Syndrome, Fragile X Syndrome

In research phase:

  • Down regulation of Th1 and/or Th17 immune responses
  • Up regulation of regulatory responses
  • Inhibition of inflammation and/or stimulation of resolution phase

In development phase:

  • Lupus
  • Primary Sjogren’s syndrome
  • Systemic Sclerosis
  • Other immune-inflammatory and auto-immune diseases with similar pathophysiological mechanisms and high unmet medical needs like auto-immune digestive diseases

 

OUR ALLIANCES

We currently have more than 50 active alliances with biotech and pharmaceutical companies across all our areas of activity:

If you wish to submit a project, please fill out the following form.




Contact
form

[recaptcha]



MEET
US

 

Each year, our teams take part in around 40 international scientific conferences. If you would like to meet us, talk with us, or propose a project, here is a list of the main partnering events for 2018:

10 February
AUTM Austin TX (USA)
11 February
BIO CEO & Investor New York (USA)
5 March
BIO-Asia Tokyo (Japan)
11 March
ASAP Global Alliance Summit Fort Lauderdale FL (USA)
16 March
ACC New Orleans (USA)
25 March
BIO-Europe Spring (EBD/BIO) Vienna (Austria)
See more